FDA-Approved AUSTEDO™

New Medication For Huntington's Disease & Tardive Dyskinesia

PharMerica: Austedo Approved For The Treatment Of Huntington’s Disease – Related Chorea

As Huntington’s disease progresses and symptoms increase, many residents of independent and assisted living communities will transition to long-term care facilities (LTC). If you’re a facility treating patients and residents who have been prescribed AUSTEDO for the treatment of Huntington’s disease – related chorea, PharMerica can help.

PharMerica, a national provider of long-term care pharmacy services, has been selected to dispense AUSTEDO for treatment of chorea associated with Huntington’s disease.

PharMerica selected by Teva Pharmaceuticals to dispense AUSTEDO™

On April 3, 2017, the U.S. Food and Drug Administration approved AUSTEDO™ (deutetrabenazine), manufactured by Teva Pharmaceuticals. AUSTEDO™ is indicated for the treatment of chorea associated with Huntington’s Disease.

Teva Pharmaceuticals has elected to distribute AUSTEDO™ through three select pharmacies. PharMerica is pleased to inform you that it has been selected by Teva Pharmaceuticals as one of those pharmacies.

AUSTEDO™ has been clinically shown to decrease the Total Maximal Chorea Score in patients by 4.4 points based on the Unified Huntington’s Disease Rating Scale (UHDRS).

AUSTEDO™ has a Black Box Warning for DEPRESSION AND SUICIDALITY, for increasing the risk of depression and suicidal thoughts and behavior. Balance risks of depression and suicidality with the clinical need for treatment of chorea when considering the use of AUSTEDO™.

Please enter the following information for more details.









Please prove you are human by selecting the House.

About Tardive Dyskinesia

Tardive dyskinesia (TD) is a disorder that involves involuntary movements. The movements most often affect the lower face. Tardive means delayed and dyskinesia means abnormal movement.

About Huntington's Disease

Huntington’s Disease is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability (cognition).

Source: US National Library of Medicine

If your facility is presently treating any resident diagnosed with Huntington’s Disease or Tardive Dyskinesia and their attending physician desires to prescribe them AUSTEDO™, PharMerica is ready to assist your facility in securing this medication for your resident. We look forward to helping you.

To order an AUSTEDO™ prescription please
contact PharMerica by phone at 1-800-678-7575 press
option #3, or fax at 1-844-602-0231.

Click below to view our Special Edition InformRx Newsletter.

PharM InformRx Special Ed June 2017

Please enter the following information and the info sheet will be immediately provided to you.









Please prove you are human by selecting the Cup.